MapLight Accelerates Phase 2 Trial Timelines for Schizophrenia and Autism Studies
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 09 2026
0mins
Source: Globenewswire
- Clinical Trial Progress: MapLight Therapeutics' ZEPHYR trial is accelerating enrollment, with topline results for 300 schizophrenia patients now expected in Q3 2026, showcasing the company's efficient execution under high-quality standards.
- IRIS Trial Update: The IRIS trial has completed enrollment, with topline results for approximately 160 autism patients also anticipated in Q3 2026, further enhancing the company's research capabilities in central nervous system disorders.
- Strategic Commitment: CEO Chris Kroeger emphasized that the rapid enrollment pace not only narrows timing guidance but also demonstrates the company's commitment to advancing its programs, potentially boosting investor confidence and attracting more funding support.
- Market Potential: With a focus on developing drugs for mental health disorders, MapLight is positioned to fill the market gap for specific therapies as clinical trials progress, driving future business growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MPLT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MPLT
Wall Street analysts forecast MPLT stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 29.780
Low
28.00
Averages
31.00
High
34.00
Current: 29.780
Low
28.00
Averages
31.00
High
34.00
About MPLT
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients suffering from debilitating central nervous system disorders (CNS). Its lead product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist, ML-007, co-formulated with a peripherally acting anticholinergic (PAC), which it is initially developing for the treatment of schizophrenia and Alzheimer’s disease psychosis (ADP). ML-007C-MA is designed to activate both M1 and M4 muscarinic receptors in the CNS to drive efficacy, while synchronizing the pharmacokinetics of the agonist and antagonist components to mitigate peripheral cholinergic side effects. Its second product candidate, ML-004, is a 5-HT1B/1D agonist that the Company is developing for the treatment of social communication deficit and/or irritability in autism spectrum disorder. It is also advancing two preclinical programs, ML-021 and ML-009.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FCPM III Reduces Stake in Dyne Therapeutics by $14 Million
- Stake Reduction Details: On May 15, 2026, FCPM III Services B.V. sold 818,460 shares of Dyne Therapeutics, valued at approximately $14.11 million, indicating that despite the reduction, the fund maintains a significant position of 11.8% in the company.
- Market Performance Analysis: As of May 14, 2026, Dyne Therapeutics shares were priced at $18.28, reflecting a 56% increase over the past year, outperforming the S&P 500 by 28 percentage points, showcasing the company's robust growth potential in the biotechnology sector.
- R&D Progress Update: Dyne recently submitted a Biologics License Application to the FDA for its lead drug z-rostudirsen, targeting a potential U.S. launch in Q1 2027 if accelerated approval is granted, marking a significant milestone in muscle disease treatment.
- Investor Considerations: Despite the stake reduction, Dyne remains FCPM's second-largest holding, reflecting the fund's confidence in the company's future, particularly at a pivotal moment for translating clinical data into commercial success.
See More
Wall Street's Latest Rating Changes Overview
- Openlane Upgrade: JPMorgan upgraded Openlane from neutral to overweight and raised its December 2026 price target to $38, indicating that the online used car marketplace is experiencing robust growth and has potential for sustainable expansion over the coming years.
- Dollar General Downgrade: Deutsche Bank downgraded Dollar General from buy to hold, citing challenges in its customer base and the widening gap in the K-shaped economy, which may limit same-store sales upside, reflecting a cautious outlook on the company.
- Ecolab Upgrade: UBS upgraded Ecolab from neutral to buy and raised its price target to $325, demonstrating strong demand and positive performance expectations for the chemicals company amid a favorable market environment.
- FedEx Upgrade: JPMorgan upgraded FedEx from neutral to overweight, expressing optimism ahead of its upcoming earnings report, particularly regarding the separation of its freight business, which is seen as an attractive risk-reward opportunity.
See More
MapLight CFO's Stock Sale Raises Investor Concerns
- Stock Sale Overview: Setia Vishwas, CFO of MapLight Therapeutics, sold 36,371 shares of common stock through multiple open-market transactions from May 4 to May 6, 2026, totaling approximately $1.02 million, indicating liquidity in his holdings.
- Ownership Change Analysis: This transaction reduced Vishwas's direct common stock holdings by 9.3%, leaving him with 356,256 shares, and while the sale was significant, it does not reflect a shift in his long-term confidence in the company.
- Trading Plan Context: The stock sale was executed under a Rule 10b5-1 trading plan adopted by Vishwas on December 29, 2025, suggesting that the sale was based on predetermined criteria rather than a direct indication of the company's future performance.
- Market Performance and Outlook: As of May 6, 2026, MapLight's stock has gained 70.8% over the past year, and despite the company being unprofitable, the expansion of its clinical pipeline and upcoming data releases may attract investor interest.
See More
MapLight Therapeutics Reports Q1 Losses and Cash Position
- Financial Performance: MapLight Therapeutics reported a GAAP EPS of -$1.34 for Q1 2026, indicating significant challenges in profitability and reflecting ongoing financial pressures on the company.
- Net Loss Overview: The net loss for the first quarter reached $60.7 million, a substantial increase from $22.3 million in Q1 2025, highlighting the urgent need for improvements in cost control and revenue growth.
- Cash Position: At the end of the quarter, the company had $395.2 million in cash, cash equivalents, and investments, which is expected to fund operations through 2027, indicating relative liquidity in the short term.
- Future Outlook: Despite the current financial difficulties, the ample cash reserves provide the company with opportunities to continue research and operations, and if it can effectively manage costs and drive revenue growth, it may achieve profitability in the future.
See More
MapLight Therapeutics Executive Sells Shares
- Executive Stock Sale: Jonathan Gillis, Chief Administrative Officer of MapLight Therapeutics, disclosed the direct sale of 69,835 shares of common stock on April 27 and 28, 2026, totaling approximately $2.09 million, indicating a strategic liquidity management approach.
- Transaction Plan Context: This sale was executed under a Rule 10b5-1 trading plan established on December 26, 2025, suggesting that it was a pre-scheduled routine transaction rather than an impulsive sell-off, thereby mitigating insider trading concerns.
- Shareholding Changes: Post-transaction, Gillis retains 181,219 shares of common stock, valued at around $5.49 million, reflecting his continued confidence in the company's future prospects.
- Market Reaction and Analysis: Although Gillis's sale contributed to an 8.63% drop in stock price, analysts remain optimistic about MapLight's potential, citing its innovative focus on central nervous system therapeutics as a significant market opportunity.
See More
MapLight Completes Enrollment in Schizophrenia Trial
- Trial Enrollment Completed: MapLight Therapeutics has completed enrollment of 307 schizophrenia patients in its Phase 2 ZEPHYR trial, marking a significant milestone as the company advances mid-stage programs, with topline results expected by mid-August 2026, potentially impacting future growth positively.
- IRIS Trial Progress: Concurrently, the IRIS trial has also enrolled 161 participants with autism spectrum disorder, including over 100 adolescents, with the primary endpoint assessing changes in social communication skills over 12 weeks, demonstrating the company's ongoing commitment to CNS disorders.
- Strong Market Demand: CEO Chris Kroeger highlighted that robust enrollment reflects the significant unmet needs in central nervous system disorders, indicating the strategic importance of the company's research and development efforts in this area.
- Stock Performance: MPLT's stock has traded between $12.24 and $33.28 over the past year, closing at $31.87 on Thursday with a 5.22% increase, suggesting positive market expectations regarding the company's future potential.
See More
FCPM III Reduces Stake in Dyne Therapeutics by $14 Million
- Stake Reduction Details: On May 15, 2026, FCPM III Services B.V. sold 818,460 shares of Dyne Therapeutics, valued at approximately $14.11 million, indicating that despite the reduction, the fund maintains a significant position of 11.8% in the company.
- Market Performance Analysis: As of May 14, 2026, Dyne Therapeutics shares were priced at $18.28, reflecting a 56% increase over the past year, outperforming the S&P 500 by 28 percentage points, showcasing the company's robust growth potential in the biotechnology sector.
- R&D Progress Update: Dyne recently submitted a Biologics License Application to the FDA for its lead drug z-rostudirsen, targeting a potential U.S. launch in Q1 2027 if accelerated approval is granted, marking a significant milestone in muscle disease treatment.
- Investor Considerations: Despite the stake reduction, Dyne remains FCPM's second-largest holding, reflecting the fund's confidence in the company's future, particularly at a pivotal moment for translating clinical data into commercial success.
See More
Wall Street's Latest Rating Changes Overview
- Openlane Upgrade: JPMorgan upgraded Openlane from neutral to overweight and raised its December 2026 price target to $38, indicating that the online used car marketplace is experiencing robust growth and has potential for sustainable expansion over the coming years.
- Dollar General Downgrade: Deutsche Bank downgraded Dollar General from buy to hold, citing challenges in its customer base and the widening gap in the K-shaped economy, which may limit same-store sales upside, reflecting a cautious outlook on the company.
- Ecolab Upgrade: UBS upgraded Ecolab from neutral to buy and raised its price target to $325, demonstrating strong demand and positive performance expectations for the chemicals company amid a favorable market environment.
- FedEx Upgrade: JPMorgan upgraded FedEx from neutral to overweight, expressing optimism ahead of its upcoming earnings report, particularly regarding the separation of its freight business, which is seen as an attractive risk-reward opportunity.
See More
MapLight CFO's Stock Sale Raises Investor Concerns
- Stock Sale Overview: Setia Vishwas, CFO of MapLight Therapeutics, sold 36,371 shares of common stock through multiple open-market transactions from May 4 to May 6, 2026, totaling approximately $1.02 million, indicating liquidity in his holdings.
- Ownership Change Analysis: This transaction reduced Vishwas's direct common stock holdings by 9.3%, leaving him with 356,256 shares, and while the sale was significant, it does not reflect a shift in his long-term confidence in the company.
- Trading Plan Context: The stock sale was executed under a Rule 10b5-1 trading plan adopted by Vishwas on December 29, 2025, suggesting that the sale was based on predetermined criteria rather than a direct indication of the company's future performance.
- Market Performance and Outlook: As of May 6, 2026, MapLight's stock has gained 70.8% over the past year, and despite the company being unprofitable, the expansion of its clinical pipeline and upcoming data releases may attract investor interest.
See More
MapLight Therapeutics Reports Q1 Losses and Cash Position
- Financial Performance: MapLight Therapeutics reported a GAAP EPS of -$1.34 for Q1 2026, indicating significant challenges in profitability and reflecting ongoing financial pressures on the company.
- Net Loss Overview: The net loss for the first quarter reached $60.7 million, a substantial increase from $22.3 million in Q1 2025, highlighting the urgent need for improvements in cost control and revenue growth.
- Cash Position: At the end of the quarter, the company had $395.2 million in cash, cash equivalents, and investments, which is expected to fund operations through 2027, indicating relative liquidity in the short term.
- Future Outlook: Despite the current financial difficulties, the ample cash reserves provide the company with opportunities to continue research and operations, and if it can effectively manage costs and drive revenue growth, it may achieve profitability in the future.
See More
MapLight Therapeutics Executive Sells Shares
- Executive Stock Sale: Jonathan Gillis, Chief Administrative Officer of MapLight Therapeutics, disclosed the direct sale of 69,835 shares of common stock on April 27 and 28, 2026, totaling approximately $2.09 million, indicating a strategic liquidity management approach.
- Transaction Plan Context: This sale was executed under a Rule 10b5-1 trading plan established on December 26, 2025, suggesting that it was a pre-scheduled routine transaction rather than an impulsive sell-off, thereby mitigating insider trading concerns.
- Shareholding Changes: Post-transaction, Gillis retains 181,219 shares of common stock, valued at around $5.49 million, reflecting his continued confidence in the company's future prospects.
- Market Reaction and Analysis: Although Gillis's sale contributed to an 8.63% drop in stock price, analysts remain optimistic about MapLight's potential, citing its innovative focus on central nervous system therapeutics as a significant market opportunity.
See More
MapLight Completes Enrollment in Schizophrenia Trial
- Trial Enrollment Completed: MapLight Therapeutics has completed enrollment of 307 schizophrenia patients in its Phase 2 ZEPHYR trial, marking a significant milestone as the company advances mid-stage programs, with topline results expected by mid-August 2026, potentially impacting future growth positively.
- IRIS Trial Progress: Concurrently, the IRIS trial has also enrolled 161 participants with autism spectrum disorder, including over 100 adolescents, with the primary endpoint assessing changes in social communication skills over 12 weeks, demonstrating the company's ongoing commitment to CNS disorders.
- Strong Market Demand: CEO Chris Kroeger highlighted that robust enrollment reflects the significant unmet needs in central nervous system disorders, indicating the strategic importance of the company's research and development efforts in this area.
- Stock Performance: MPLT's stock has traded between $12.24 and $33.28 over the past year, closing at $31.87 on Thursday with a 5.22% increase, suggesting positive market expectations regarding the company's future potential.
See More
